“genzyme” Archives

in
Entry Author Date Location
X4 Completes Reverse Merger with Arsanis, Looks Ahead to Phase 3 Test 03/13/19 Boston
X4 Pharma Heads to Nasdaq Via Reverse Merger with Arsanis 11/27/18 Boston
With CRISPR’s Help, KSQ Touts 13 Cancer Drugs and Bags Another $80M 09/28/18 Boston
LogicBio Jumps on the Gene Therapy 2.0 Wave and Lines Up an IPO 09/26/18 Boston
Bio Roundup: Funding Frenzy, Opioid Summit, Celgene Woes & More 03/02/18 National
Avrobio Raises $60M for Fabry Disease Gene Therapy, Rest of Pipeline 02/01/18 Boston
After Humanitarian Honor, Flagship’s Afeyan States Case for Immigration 12/06/17 Boston
Ed Kaye on Sarepta’s Duchenne Quest, Rising to CEO & His New Startup 11/20/17 Boston
X4 Pharma Pulls In $27M for Immune Drug in Cancer, Rare Diseases 11/16/17 Boston
Sanofi Pulls Back from Voyager Gene Therapy Pact in Parkinson’s 10/31/17 Boston
The Winners of the Xconomy Lifetime Achievement Award Are… 09/12/17 Boston
Startup Builders, IPO Closers & More: Meet Xconomy’s CEO Award Finalists 08/10/17 Boston
Bio Leaders Mourn Passing of Genzyme Exec, Orphan Drug Innovator Termeer 05/14/17 Boston
Stalled or Rising Momentum? New York Wrestles With Its Biotech Future 05/10/17 New York
Bio Roundup: Gottlieb Talks Vax, Acorda’s Axe, Adams, 23andMe & More 04/07/17 National
Boston Startup Exit Data Show Region’s Shift From Tech to Healthcare 04/04/17 Boston
At Arrakis, Gilman Teams With Biogen Vets to Target RNA With Pills 02/27/17 Boston
Voyager’s Gene Therapy for Parkinson’s Shows Promise in Small Study 12/07/16 Boston
Amicus Shares Fall On Another Bump in Rough Road To U.S. Fabry Nod 11/28/16 New York
Should We Rewrite the Human Genome? 11/28/16 Boston
Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More 09/30/16 National
Amylyx Nabs $5M to Take Aim at Nerve Cell Death in ALS Patients 08/22/16 Boston
Audentes Prices $75M IPO As Gene Therapy Eyes First U.S. Approval 07/20/16 San Francisco
Alnylam Advances RNAi Drug Results After Two Years of Treatment 07/01/16 Boston
Vedanta Nabs $50M To Expand Microbiome Into Immune-Boosting Therapies 06/06/16 Boston
Near-Term FDA Nod Unlikely For Duchenne Drug After Negative Vote 04/25/16 Boston
For San Antonio’s Consideration: A Biotech Incubator and Accelerator 04/08/16 Texas
At Long Last, First Drug Approval in Sight for Amicus 04/01/16 New York
East Coast Bio Roundup: PCSK9 Battle, NYU Startups, Blueprint & More 03/17/16 Boston
Proteostasis Cuts Price But Heads to Nasdaq After $50M IPO 02/11/16 Boston
Page 1 of 17 next page »